Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px
Document › Details

Lonza Group Ltd.. (10/3/17). "Press Release: Lonza to Acquire a U.S. Clinical Manufacturing Site to Support Ongoing Customer Demand". Basel.

Organisations Organisation Lonza Group AG
  Today Lonza Group (Group)
  Group Lonza Group (Group)
  Organisation 2 Shire plc, Clinical Manufacturing Site in Hayward, CA, USA
  Today Lonza Clinical Manufacturing Site in Hayward, CA, USA
  Group Lonza Group (Group)
Products Product biopharmaceutical
  Product 2 contract manufacturing (biologicals)
Persons Person Fallen, Karen (Lonza 201308 VP Licensing + Technology Lonza Development Services)
  Person 2 Oehlers, Dirk (Lonza 201610 Head Investor Relations)
     


> Site is being acquired from Shire plc and adds early-phase clinical manufacture on the West Coast

> Capacity includes 1,000L and 2,000L single-use bioreactors, all associated media & buffer prep and downstream purification capabilities

> Facility will complement existing clinical assets in Slough (UK) and enhance Lonza’s capability to support its customers’ products throughout their lifecycle

> All 100+ former Shire site personnel will have opportunity to continue in their role with Lonza


Basel, Switzerland, 3 October 2017 – Lonza announced today that it is acquiring a clinical-stage mammalian manufacturing site in the United States from Shire plc. Financial details of the deal were not disclosed.

The 58,000-square-foot (approximately 5,388-square-meter) site, located in Hayward, CA (USA), has been operating as a multiproduct cGMP facility since 1990 and has a successful regulatory track record. Assets include 1,000L and 2,000L single-use bioreactors and associated downstream capabilities. Currently the site employs more than 100 personnel, all of whom will have the opportunity to continue in their role with Lonza.

In response to Lonza’s Pharma&Biotech customers’ increasing demand for clinical-stage manufacturing capacity, the acquisition of the site will provide additional cGMP capacity and will supplement our existing assets in Slough (UK). Lonza customer batches will be initiated in 2018.

“As a committed partner to the pharmaceutical and biotechnology industry, Lonza recognizes the need for established and dependable global manufacturing facilities,” said Karen Fallen, Vice President, Business Unit Head, Clinical Development, for Lonza. "The acquisition of this site allows our customers greater access to clinical capacity from a U.S. site. The additional capacity will support the needs of our customers to secure manufacture for their products’ complete lifecycle across Lonza’s global manufacturing network."

“We are confident in Lonza’s ability to continue the important work happening in Hayward and are pleased that they recognized the talent of the team already in place,” said Matt Walker, Shire’s Head of Technical Operations. “Moving forward, Lonza will serve as a partner to Shire, managing the manufacture and supply of reagents used in a number of Shire products.”

About Lonza

Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.

An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the Lonza group provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.

Founded in 1897 in the Swiss Alps, Lonza today is a wellrespected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com.


Lonza Contact Details Dirk Oehlers, Head Investor Relations Lonza Group Ltd Tel +41 61 316 8540 dirk.oehlers@lonza.com

Dominik Werner, Head Corporate Communications Lonza Group Ltd Tel +41 61 316 8798 dominik.werner@lonza.com

Constance Ward, Head External Communications Lonza Group Ltd Tel +41 61 316 8840 constance.ward@lonza.com


Shire Contact Details Katie Joyce, Head of U.S. Corporate Affairs and Media Relations Shire plc Tel +1 617 678 9370 KJoyce@Shire.com


Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.


Lonza Ltd
Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland
+41 61 316 81 11
+41 61 316 91 11
media@lonza.com

   
Record changed: 2017-10-16

Advertisement

Picture Fairtec GmbH Worldwide Event Solutions 600x60px

More documents for Lonza Group (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Eurasanté BioFIT 2017 Strasbourg France November 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture Eurasanté BioFIT 2017 Strasbourg France November 120x80px